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Abstract
Pre-mRNA splicing is the removal of intervening sequences from pre-messenger RNA in a 
reaction catalyzed by the spliceosome, which contains five small nuclear RNAs (snRNAs) and 
more than 100 proteins. Assembly of the spliceosome occurs in a highly ordered manner, making 
the spliceosome a very complex and dynamic particle. The spliceosome has been studied in yeast 
and humans but a simpler system would simplify splicing studies. Cyanidioschyzon merolae 
{Cm) has been shown to have a simpler spliceosome.
The goal of this study was to characterize the Cm spliceosome beginning with the question of 
how large it is. To measure the size of the Cm spliceosome I used glycerol gradient 
centrifugation and assembly gels to study the assembly pathways. Lastly an attempt was made to 
study the components of Cm  spliceosome by developing an assay in yeast {Saccharom yces 
cerevisiae) where small molecule inhibitors were used to stall the spliceososme, which could 
then be purified and its composition studied.
TABLE OF CONTENTS
Abstract..................................................................................................................................................ii
Table o f Contents................................................................................................................................. iii
List of Tables........................................................................................................................................ v
List of Figures...................................................................................................................................... vi
Acknowledgements.......................................................................................................................... viii
CHAPTER 1: Pre-mRNA Splicing
1.1 Introduction............................................................................................................................... 1
1.2 The Spliceosome...................................................................................................................... 2
1.3 Mechanism of splicing.............................................................................................................2
1.4 The chemical reactions of pre-mRNA splicing.....................................................................5
1.5 Self-Splicing and Alternative splicing................................................................................... 6
1.6 Significance of splicing............................................................................................................7
CHAPTER 2: Spliceosome assembly in Cyartidioschyzon merolae
2.1 Introduction.............................................................................................................................10
2.2 Materials and m ethods........................................................................................................... 15
2.2.1 MS2 Hairpin X 3 ............................................................................................................17
2.2.2 C. merolae G enes..........................................................................................................17
2.2.3 Splicing Extract preparation........................................................................................ 17
2.2.4 Preparation of the gradient...........................................................................................20
2.2.5 Splicing A ssays.............................................................................................................20
2.2.6 Spliceosome Assembly G els ........................................................................................20
2.3 Results.....................................................................................................................................21
2.3.1 Splicing g e ls ..................................................................................................................25
2.3.2 Stalling the Cm spliceosome at different stages........................................................ 31
2.4 Discussion...............................................................................................................................35
2.5 Conclusion..............................................................................................................................37
CHAPTER 3: High-throughput assay for pre-mRNA splicing
3.1 Introduction.............................................................................................................................39
3.2 Materials and methodology................................................................................................... 41
3.2.1 Splicing assays..............................................................................................................41
3.2.2 Primer design................................................................................................................42
3.2.3 RT P C R ......................................................................................................................... 43
3.2.4 Gel assay....................................................................................................................... 44
3.2.5 QPCR analysis..............................................................................................................44
3.3 Results.....................................................................................................................................44
3.3.1 Gel A ssays....................................................................................................................45
3.3.2 QPCR analysis..............................................................................................................51
3.4 Discussion...............................................................................................................................55
3.5 Conclusion..............................................................................................................................57
CHAPTER 4: Conclusion............................................................................................................... 58
References.......................................................................................................................................... 61
iv
List of Tables
Table 1: Sequences of primers used to PCR amplify genomic DNA for 311C, 072C
and 382C ......................................................................................................................................................19
Table 2: C. merolae transcripts with their different 5' splice s ites.................................................23
Table 3: Sequences of primers designed for actin pre-mRNA as well as m RN A .........................42
Table 4: Ct (threshold cycle) values for ±ATP at 60°C and 65°C (annealing temperature) 52
Table 5: Ct (threshold cycle) difference for ±ATP at 65°C and 60°C (annealing temperature). 53
List of Figures
Figure 1: Schematic diagram showing different spliceosomal changes occurring during the 
splicing process (Schroeder et al. 2004).............................................................................................4
Figure 2: Schematic diagram of chemical reactions catalyzed by the spliceosome involving two 
transesterification steps of pre-mRNA splicing..................................................................................5
Figure 3: Schematic diagram of glycerol gradient sedimentation analysis of spliceosome size 
 12
Figure 4: Schematic diagram of the MS2 affinity purification strategy for isolation of 
spliceosomal B complexes...............................................................................................................  14
Figure 5: pUC 19 vector with restriction s ites ................................................................................ 16
Figure 6: Comparison of spliceosome assembly in 32P labelled 382C pre-mRNA and mRNA 
 22
Figure 7: Glycerol gradient analysis of 311C, 067C and 072C ......................................................24
Figure 8: Graphical representation of glycerol gradient performed in yeast system with actin 
............................................................................................................................................................... 25
Figure 9: Gel analysis showing the presence of 3XMS2 actin in p u c l9 ....................................... 27
Figure 10: Confirmation of presence of C. merolae’s genes in MS2 tagged construct................. 28
Figure 11: Standard splicing assay................................................................................................... 29
Figure 12: Splicing assays done with Cm pre-mRNAs...................................................................30
Figure 13: Kinetics of splicing complex formation.........................................................................32
Figure 14: Spliceosome assembly with actin and Cm pre-mRNAs................................................33
Figure 15: Comparison of spliceosome assembly in yeast and Cm splicing extracts..................34
Figure 16: Block diagram of primers designed for actin pre-mRNA and m RN A .........................43
Figure 17: Measurement of efficiencies of phenol/chloroform extracted splicing reactions with 
primer B .............................................................................................................................................. 46
Figure 18: Identification of appropriate annealing temperature for primer A by selecting different 
gradients...............................................................................................................................................47
Figure 19: Splicing efficiency for identification of appropriate annealing temperature for primer 
C (spliced specific).............................................................................................................................48
Figure 20: Measurement of efficiencies of both crude and phenol-chloroform extracted splicing 
reactions with primer B ...................................................................................................................... 49
Figure 21: Confirmation of efficiencies of crude splicing reaction using primer B again by 
making different sets o f dilutions..................................................................................................... 50
Figure 22: Difference in Ct values for +ATP vs -ATP at 60°C and 65°C.......................................54
Acknowledgements
I would like to show my deepest gratitude to my supervisor Dr. Stephen Rader for his guidance, 
mentoring, and encouragement throughout my Master’s thesis. Many thanks to Dr. Martha Stark 
and Dr. Jeff Northrop for their keen and vigorous academic observation that enlightens me not 
only in this thesis but also in my future study. Thanks to my committee members Dr. Kerry 
Reimer and Dr. Sarah Gray for their helpful comments and suggestions. I am also grateful to my 
lab members for their friendships and discussions on research, and especially Elizabeth Dunn for 
her help during my research.
I would like to thank my parents for their support and love throughout my academic endeavors. 
Finally I would like to acknowledge my husband Siraj U1 Islam for his unpremeditated support 
and who contributed a lot in the development of my scientific skills as a researcher.
CHAPTER 1
Pre-mRNA Splicing
1.1 Introduction
Proteins carry out many cellular functions and are synthesized according to the information 
contained in DNA. This information is transferred from DNA to messenger RNA (mRNA) in the 
process of transcription. Both DNA and RNA are nucleic acids, consisting of sugar-phosphate 
backbones with nitrogenous bases that form hydrogen bonds to each other in A-T and G-C pairs. 
When mRNA is first transcribed from one of the strands of DNA, it is called pre-mRNA. It 
contains the sequences for protein synthesis, exons, along with non-coding sequences, introns. 
The introns are removed from the pre-mRNA through the process of splicing. Splicing is an 
essential process for the production o f functional proteins. The removal of introns and ligation of 
exons must occur before the mRNA transcript is transported to the cytoplasm for protein 
synthesis.
The phenomenon of pre-mRNA splicing, in which introns are excised such that only exons 
remain, has been found to occur in all domains of life although the number of genes spliced and 
the mechanism by which it occurs can vary distinctly. The process of splicing is vital for the 
eukaryotic cell, and when the process is blocked, the cell dies. The reason splicing is an essential 
process in the cell is because, after transcription, the pre-mRNA contains both intronic and 
exonic sequences. The exonic sequence contains protein coding portions of the RNA whereby 
codons directly specify which amino acids will be incorporated into a newly synthesized protein. 
Conversely, the intronic sequences are non-coding portions of the pre-mRNA which need to be
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removed in order to form an uninterrupted sequence known as mature mRNA. If introns are not 
removed from pre-mRNA, the cell cannot synthesize the protein coded by the mRNA, usually 
resulting in truncated or mutated proteins that lack functional integrity.
1.2 The Spliceosome
The spliceosome is a large, catalytic protein-RNA complex responsible for removing introns and 
ligating exons to form mature mRNA. In size and complexity, the spliceosome is comparable to 
the ribosome. The spliceosome is made up of five small nuclear RNAs (snRNAs) that are 
particularly rich in uridine residues and are thus known as U l, U2, U4, U5, and U6 (Zhou et al. 
2002; Ruby et al. 1991). These five snRNAs interact with distinct proteins to form five small 
nuclear ribonucleoproteins (snRNPs). The human spliceosome is composed of more than 50 
proteins associated with snRNPs and over 100 non-snRNP proteins (Wahl et al. 2009), whereas 
in yeast there are about 90 proteins that are involved in splicing (Will et al. 2010). The number of 
components involved in the interaction between snRNPs and pre-mRNA contribute to the 
dynamic nature of splicing. As the number of proteins required for each stage of splicing varies 
substantially from one stage o f splicing to the next, the spliceosome undergoes various 
conformational changes resulting in the removal of introns and ligation of exons. Changes in 
spliceosomal conformations are very complicated and dynamic as shown in Figure 1 (taken from 
Schroeder et al. 2004). Once the mature mRNA is formed and the intron is degraded, the snRNPs 
are returned to their original conformations to be recycled through future rounds of splicing 
(Staley and Guthrie 1998).
1.3 Mechanism of splicing
2
The mechanism of splicing has been studied in various organisms and follows a general trend. 
Introns are removed from RNA by cleavage at splice sites present at the 5' and 3' ends of introns. 
The RNA sequence that is removed commonly begins with the dinucleotide GU at its 5' end and 
ends with AG at its 3' end. These consensus sequences are known to be critical because altering 
any one of the conserved nucleotides results in splicing inhibition. Another important sequence 
occurs at the branch point, which always contains an adenine. The process of splicing occurs in 
several steps and is catalyzed by the spliceosome. One of the most important jobs of the 
spliceosome is to identify the ends of introns accurately and efficiently and bring them together 
to promote the chemistry of splicing. The assembly of the spliceosome begins with the binding 
of U1 small nuclear ribonucleic protein (snRNP) at the 5' end of the intron. Subsequently, the U2 
snRNP forms a base-pairing interaction with the branch point followed by the participation of the 
U4/U6*U5 tri-snRNP. Following the addition of the tri-snRNP, a number o f rearrangements 
occur that cause the spliceosome to become catalytically active. Binding of U1 at the 5'ss is 
replaced by U6, and base-pairing between U4 and U6 small nuclear RNA (snRNA) is disrupted 
with the formation of mutually exclusive interactions between U2, U6 (Madhani and Guthrie 
1994) and U5 (Guthrie and Patterson 1988). The result of these exchanges is the release of U1 
and U4 from the spliceosome, leaving U2 and U6 bound to the branch point and 5'ss, 
respectively, with U5 interacting with the two exons.
3
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Figure 1: Schematic diagram depicting spliceosomal formation changes occurring during the 
splicing process (Schroeder et al. 2004).
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1.4 The chemical reactions of pre-mRNA splicing
It is known that two transesterification reactions are involved in splicing (Aulma et al. 1997).
The phosphate at the 5' splice site undergoes nucleophilic attack by the 2' hydroxyl of the branch
point adenosine resulting in free 5' exon and an intron-exon lariat due to formation of a
phosphodiester bond between branch point adenosine and 5' end of intron (Guthrie 1991, Green
1991). In the second reaction, the 3' splice site is attacked by the 3' hydroxyl group o f the 5' exon
resulting in the conjugation of the 5' and 3' exons (forming the mRNA) and release of the intron
lariat. Two transesterification reactions of splicing are shown in Figure 2 (Brow 2002). This
Figure (From Brow 2002) explains how mature mRNA is synthesized from pre-mRNA in
spliceosome catalyzed chemical reactions.
5’ splice site „  -  '  "  v ^ 3' splice site
\ o  oh \ o
5'---------- O-P-O-----------------------------------A------------ O-P-O------------3'
O. . . branchpoint O.5* exon intron ^  3 'exon
^transesterification 1
O-P-O*
OH O-P-O
5* exon lariat Intermediate
transesterification 2
O-P-O*
O-P-O OH 3’
lariat Intron
Figure 2: Schematic diagram of chemical reactions catalyzed by the spliceosome involving 
two transesterification steps of pre-mRNA splicing. In the first transesterification step, the 
oxygen atom of adenosine (A) residue of the intron forms a bond with the phosphorus atom at 
the end of exon, forming an intron lariat (intermediate). In the second transesterification reaction, 
the oxygen atom of the hydroxyl group of the exon forms a bond with the phosphorus atom that 
links the intron and exon, forming intron lariat and ligated exons (Brow 2002).
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1.5 Self-Splicing and Alternative splicing
Some RNA molecules have the ability to splice themselves. The self-splicing introns known as 
Group I introns form a complex secondary structure that brings about transesterification 
reactions. Group II self-splicing introns are found in mitochondrial genes and are excised by a 
process that is similar to pre-mRNA splicing (i.e. via the formation of lariats). Therefore, it has 
been proposed that spliceosomal splicing evolved from Group II introns.
Researchers have found that alternative patterns of splicing within a single pre-mRNA molecule 
also occur, producing different functional mRNAs (Berget et a l 1977). An example of 
alternative splicing was noticed in the adenovirus in 1977 that demonstrated that one pre-mRNA 
molecule could be spliced at different junctions to form a variety of mature mRNA molecules 
with different combinations of exons.
Alternative splicing was later found to occur in cellular genes like the IgM  gene (a member of 
the immunoglobulin superfamily) (Early et al. 1980) and the Dscam gene from Drosophila. 
Examination of the Dscam sequence revealed a variety o f introns that splicing could, in theory, 
convert into 38,000 different mRNAs. The ability for multiple mRNA transcripts to be generated 
from a single gene is one mechanism by which protein complexity of organisms, such as 
humans, can exist despite the fact that human genetic complexity is comparable to that of a 
worm in protein diversity. About 90% of human genes are alternatively spliced (Wang et al. 
2008). It has been shown that alternative splicing preceded multicellularity in evolution (Irimia et 
al. 2007) suggesting that this mechanism might have been adopted to assist in the development 
of multicellular organisms.
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1.6 Significance of splicing:
Pre-mRNA splicing is an important aspect of gene regulation in many organisms. Removal of 
introns from nascent transcripts is an essential step in eukaryotic gene expression. Splicing is a 
key way to generate various proteins from a single gene. The human genome has only 23,000 
protein coding genes, and it has been shown that more than 90% of these genes undergo 
alternative splicing to produce various functionally distinct proteins (Lu Chen et al. 2012).
It has been shown that for eukaryotes alternative splicing is an essential mechanism for genetic 
efficiency as information can be stored more economically. Multiple proteins can be encoded by 
a single gene, rather than requiring a separate gene for each, which results in the formation of a 
diverse proteome from a genome of limited size. The understanding of splicing at the molecular 
level is important not only in understanding gene expression, but it is also of medical relevance 
as aberrant pre-mRNA splicing is the basis of many human diseases, such as Cystic Fibrosis and 
Retinitis Pigmentosa (Ward and Cooper 2010).
Changes in the splice site may have different effects on mRNA and protein synthesis. Alternative 
splicing patterns sometimes cause the addition of a portion of coding sequence in the mRNA 
resulting in the formation of protein isoforms that differ in their peptide sequence and also in 
their chemical and biological activity.
Changes in the machinery of RNA processing may also lead to mis-splicing of transcripts. 
Mutations in any o f the splicing elements or in splicing regulatory proteins have been shown to 
be involved in human disease. It has been estimated that about two-thirds of all hereditary 
diseases involve a splicing component (Lim et al. 2011). Errors like mutations of a splice site
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may result in the loss of an exon or inclusion of an intron which ultimately may result in the loss 
of function of that site. Similarly, sometimes displacement of a splice site, leading to inclusion or 
exclusion of more RNA than expected, results in longer or shorter exons. Abnormally spliced 
mRNAs have also been found in a great proportion of cancerous cells (Skotheim et al. 2007). 
This disruption of the standard splicing pattern results in pathological conditions. In order to 
understand these diseases, it is important to understand the normal pathway of splicing.
From the pathological implications we can see that splicing is an important process that must be 
performed precisely and accurately, and thus understanding the splicing process is very 
important. Splicing has been characterized in several organisms including Homo sapiens, 
Saccharomyces cervevisiae, and, to a very small extent prior to this work, Cyanidioschyzon 
merolae.
The spliceosome has been extensively studied in humans and in yeast, for example by combining 
affinity purification methods of assembled spliceosome complexes with mass spectrometry 
(Zhou et al. 2002 and Fabrizio 2009). These studies have shown that the number of proteins vary 
substantially from one stage of splicing to another. Similarly the composition and conformation 
of the spliceosome changes dramatically during the transition from one assembly stage to 
another (Bessonov et al. 2008). For example, proteomic studies of humans revealed that more 
than 60 proteins are exchanged during the catalytic activation step of splicing. The human 
spliceosome is composed of more than 50 proteins associated with snRNPs and more than 100 
non-snRNP proteins (Wahl et al. 2009). The yeast spliceosome is also known to have similar 
assembly patterns of splicing as has been found in humans but with fewer proteins. It is known 
that more than 90 proteins are involved in splicing in yeast (Will et al. 2010). These studies have 
shown that the number of proteins per spliceosomal complex is less than half as many compared
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to humans (Fabrizio et al. 2009). Although the number of splicing factors found in human 
purified spliceosomes is higher when compared to yeast spliceosome, almost all of the identified 
splicing factors in yeast are evolutionarily conserved in humans.
The goal of this study was to characterize spliceosome assembly in a red alga, Cyanidioschyzon 
merolae, based on the protocols developed for Saccharomyces cerevisiae. C. merolae, in 
particular, is a useful organism for the study of pre-mRNA splicing because it is unicellular and 
has reduced splicing machinery and contains only 27 introns. These characteristics make it an 
interesting and potentially more tractable system in which to study this process. This study is the 
first attempt to study spliceosome assembly in C. merolae.
We specifically sought to test the hypothesis that the C. merolae spliceosome assembles on 
transcripts into a particle of a specific size. We tried three different techniques to characterize the
C. merolae (abbreviated as Cm throughout the text) spliceosome. Initially, we decided to 
measure the size of the Cm spliceosome using glycerol gradients, described in Chapter 2. As 
mentioned in Chapter 2, assembly gels were also performed in order to determine the steps in 
Cm spliceosome assembly. Lastly in Chapter 3, an assay was developed for inhibitors of splicing 
in order to stall the spliceosome at different stages for purification.
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CHAPTER 2
Spliceosome assembly in Cyanidioschyzon merolae
2.1 Introduction
The number o f introns varies among different organisms. About 90% of human genes contain 
introns, however, there are some organisms, such as Cyanidioschyzon merolae, whose genes 
contain only a few introns. This unicellular, photosynthetic red alga possesses only 27 introns 
(0.5% of its genes contain an intron) (Matsuzaki, et al. 2004). C. merolae is an acidophilic red 
alga that grows at 45°C, and its genome was the first algal genome to be sequenced. In fact it was 
the first genome of any kind to be 100% sequenced. The small number o f introns in C. merolae 
raises the question of whether C. merolae maintains the full complement of splicing machinery, 
or possesses a reduced set.
We do not have a lot of information about the function of splicing proteins in Cm, but Dr. 
Rader’s lab has uncovered a lot of information about the identity of many of the splicing 
components in Cyanidioschyzon merolae. In order to identify these components and to 
understand the process of splicing in such an organism, having only a few introns, it is important 
to confirm that all the splicing machinery is present. C. merolae’s snRNAs have been 
investigated previously in the Rader lab, where the existence of U2, U4, U5, and U6 was 
bioinformatically predicted and experimentally confirmed (Dunn 2011). Surprisingly, these 
studies were unsuccessful in identifying any candidate for the U1 snRNA, suggesting that in C. 
merolae splicing may occur without the U1 snRNP, These experiments have identified only -70 
splicing proteins in total, compared to over 200 in humans.
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The goal of this project was to study the splicing machinery of Cm by applying biochemical 
methods and studying spliceosome assembly at distinct stages. In particular, we sought to test the 
hypothesis that the Cm splicing machinery assembles on pre-mRNA transcripts as in yeast, that 
is, as a particle of a fixed size. The specific aims were: first, to determine the size of the splicing 
complex in C. merolae so that the experimental value could be compared with our computational 
predictions of the composition of the spliceosome; and, second, to purify splicing components 
and identify them by mass spectrometry. To accomplish these goals, glycerol gradient 
centrifugation and assembly gels were performed in order to study spliceosome assembly in C. 
merolae.
We do not know much about the composition of the spliceosome and the mechanisms involved 
in catalyzing the splicing process. Glycerol gradient sedimentation is a technique that has been 
used to study spliceosome assembly and purify splicing particles. This technique has been mostly 
used to study spliceosome assembly in yeast and humans. For example, spliceosome assembly 
was detected in yeast extract by glycerol gradient sedimentation (Brody et al. 1985). They 
analyzed the splicing reactions of pre-mRNA in yeast extract by glycerol gradient centrifugation 
and found that all the pre-mRNA and splicing intermediates (spliceosome) lie in the 40S peak 
after pre-mRNA enters into the first round of splicing.
To determine, first, whether Cm extract was competent of spliceosome assembly and, second, to 
determine the size of any splicing particles that form, we decided to study spliceosome assembly 
by glycerol gradient sedimentation. This technique is a direct way to study spliceosome assembly 
as it does not involve any gels or other components that may interfere with the RNA (such as 
heparin and dye that are added to samples before loading onto a gel). The primary function of 
glycerol gradient centrifugation is to separate particles on the basis of their rate of sedimentation.
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As shown in Figure 3, particles of different sizes in a suspension will sediment at different rates 
with the larger particles sedimenting faster. Here, we describe the gradient centrifugation 
procedure to study the spliceosomal complexes which can be subjected to downstream 
applications, such as affinity purification.
A D
Sample Zone D
Figure 3: Glycerol gradient sedimentation: Sample is layered on top of gradient (A). Particles 
sediment at different rates depending on their size and shape, with bigger particles sedimenting 
faster (B).
When a splicing reaction is layered on top of the gradient, particles in a centrifugal field move at 
different rates depending on their mass and frictional coefficient, which is determined by their 
shape and interactions with solvent. The size of the splicing complex is determined from the 
sedimentation behaviour of the RNA. As radioactively labelled RNA is used, each gradient 
fraction can be counted for radioactivity with the use of a scintillation counter. RNA without 
associated splicing complexes is expected to remain at the top of the gradient, so peaks of 
radioactivity further down the gradient indicate the presence of something bound to the RNA.
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Control splicing reactions with in vitro transcribed mRNA (intronless) confirmed that particle 
assembly on pre-mRNA was intron-dependent and, therefore, relevant to splicing.
Similarly, an attempt was made here to study the assembly steps in Cm by performing assembly 
gels. The assembly gel is a good technique to study spliceosome assembly and has been used by 
many researchers. These kinds of gels can help distinguish between distinct spliceosome stages 
involved in splicing by using the splicing assay at different time points and studying it on a 
native assembly gel. This technique has been used previously to study spliceosome in yeast and 
in human (Fabrizio et al. 2009; Deckert J et al. 2006). These experiments have been designed 
with assembly gels to stall the spliceosome at different intermediate steps in order to study the 
composition and pathways of this complex. We now know, for example, that there are at least 
four distinguishable intermediate complexes (A, B, Bact, and C) during the assembly and catalytic 
steps of the splicing reaction. To characterize the intermediate complexes, affinity purification 
was used by these researchers. Figure 4 shows the affinity purification method as used on the 
yeast spliceosome (taken from Deckert J et al. 2006).
The coat protein of MS2 bacteriophage binds to a defined stem-loop RNA structure that has been 
used to affinity purify RNA protein complexes in other organisms (Das et al. 2000). An MS2- 
tagged pre-mRNA transcript from C.merolae was made to purify assembled spliceosome 
components using an MS2-MBP fusion protein and amylose resin. In order to isolate 
spliceosome intermediate complexes, ideally those that may contain C.merolae U l, the first step 
was to compare in vitro splicing of tagged versus untagged C.merolae pre-mRNAs. As a test of 
this methodology, we used yeast splicing extract and yeast actin (untagged and MS2-tagged), 
subsequently making splicing extracts from C.merolae using protocols developed for yeast and 
testing them on yeast and C.merolae pre-mRNAs for splicing.
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R
Figure 4: Schematic diagram of the MS2 affinity purification strategy for isolation of 
spliceosomal B complexes. Pre-mRNA tagged at its 3' end with three RNA binding sites of the 
MS2 coat protein was pre-incubated with a fusion protein of the MS2 coat protein and MBP 
(step I). Subsequently, nuclear extract was added and spliceosomes were allowed to form for 8 
min (step II). Complexes were then fractionated by size on a linear 10 to 30% glycerol gradient 
(step III). Spliceosomal B complexes from the 40S peak fractions were affinity selected using 
amylose beads and subsequently eluted with maltose (step IV) (Deckert et al. 2006).
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The final step was to purify MS2-MBP protein by amylose and heparin chromatography, and use 
the MS2-MBP fusion protein to demonstrate that MS2-tagged pre-mRNAs could be purified.
This chapter mainly focuses on the investigation of spliceosome assembly in Cm. For this 
purpose the spliceosome was studied by glycerol gradient centrifugation and assembly gels both 
in yeast and Cm. Our assembly gels were not used further for purification of splicing 
intermediate complexes as we were unable to get splicing complexes in Cm. The MS2-tagged 
constructs designed specifically for purification analysis were thus used only in assembly gels 
and glycerol gradients. In order to better understand the splicing mechanism in Cm, in-vitro 
splicing assays were also performed both in yeast and Cm. All the experiments in yeast (splicing 
and assembly gels), described here, were used previously to define the standard splicing 
assembly pathway as we have seen in the literature; therefore, we studied spliceosome assembly 
in C. merolae by applying the same strategies.
2.2 Materials and methods
For the affinity purification method with the MS2 MBP fusion protein, the first step is to make 
an MS2 tagged construct and then an MS2 MBP fusion construct. For this purpose the pUC19 
plasmid (2686bp) was selected. The MS2 hairpin and C. merolae genes were cloned into the 
plasmid by digesting it with restriction enzymes and then ligating the appropriate fragments into 
the vector as shown in Figure 5. Initially 3XMS2 actin was made in pBluescript (pBS). For this 
purpose, pBS plasmid with an insert of actin was taken and digested with EcoRI to remove the 
EcoRI site from it. This new plasmid named pSR499 was then digested with Sacl. The annealed 
oligos for 3XMS2 described in section 2.2.1 were also digested with Sacl, gel extracted and 
cloned into Sacl-digested pSR499. This 3XMS2 tagged actin was later cloned into pUC19 by
15
digesting the plasmid with BseYI. PUC19 was also digested with Sacl, T4 blunted and both the 
vector (pUC19) and insert (3XMS2 actin) were gel isolated and cloned together by ligation. Next 
Cm genes were cloned into pUC19 by cutting it with EcoRI and BamHI, in order to remove 
actin, and cloning Cm PCR fragments (digested with EcoRI and BamHI) into it.
QC —
3XMS2
Actin I 
Pre-mRNA
2686bp
pUC19
Figure 5: This vector is 2,686 base pairs in length. 3XMS2 actin with T7 sequence was removed 
from pBS by cutting it with BseYI and then ligating it into pUC19.
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2.2.1 MS2 Hairpin X3
Two oligos encoding the MS2 hairpins were annealed by PCR and then gel extracted. Sequences 
of these oligos with MS2 hairpin are:
FWD
5'CCGGAGCTCGATATCCGTACACCATCAGGGTACGAGCTAGCCCATGGCGTACACC 
ATCAGGGTACGA 3'
REV
5'GGCGAGCTCGAATTCCGTACCCTGATGGTGTACGAGATCTACTAGTCGTACCCTGA 
TGGTGTACGC 3'
A transcription template for 3XMS2 tagged pre-mRNA was made by overlapping PCR of the 
pre-mRNA and 3XMS2 PCR product.
2.2.2 Amplification of C. merolae Genes
Genomic DNA of C. merolae, a kind of gift of Dr. Martha Stark, was used as a template for PCR 
with the primers given in Table 1. MS2 tagged and untagged transcripts were made by cloning 
the PCR-amplified genes into pUC19 and then transcribed in vitro to generate pre-mRNAs. For 
each gene from C. merolae, the appropriate pairs of (Forward and Reverse) oligos were used. 
Sequences of all these pairs are given in Table 1.
2.2.3 Splicing Extract preparation
Yeast whole-cell extract was prepared according to (Ansari and Schwer 1995). 4L culture of 
strain BJ2168 was grown to OD 1.8-2.0. Cells were harvested at 3000rpm in JA8.1000 for 15
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min at 4°C. After this step cells were kept on ice. Cell pellets were washed with 50ml cold 
ddH20, resuspended and spun again at 3000rpm in JA8.1000 for 10 min at 4°C. Second wash 
was performed with 50ml cold AGK buffer (lOmM Hepes-KOH 7.9, 1.5mM MgCh, 200mM 
KC1, 0.5mM DTT and 10% glycerol). Pellets were spun again at 3,000 rpm for lOmin and 
resuspended in 7.5mL AGK buffer. Cell pellets were then transferred to 50mL conical tube and 
kept frozen with liquid nitrogen. Frozen cell beads and liquid nitrogen were poured in pre-cooled 
mortar and pestle and cells were grinded into a very fine powder. Powder was then transferred to 
250mL beaker, stirred for 30 min on ice water bath and transferred with 5mL pipet to oakridge 
tube to spin in JLA 25.5 at 18,000 rpm for 30 min. Supernatant from tube was taken carefully 
and spun at 37,000 rpm for lhr. Dialysis was performed twice in buffer D (20mM Hepes-KOH 
7.9, 0.2mM EDTA, 50mM KC1, 0.5mM DDT, 20% glycerol) for 1.5 hrs each. 50-100 pi aliquots 
were made in liquid nitrogen and kept at -80°C.
C. merolae whole cell splicing extracts were kindly provided by Dr. Martha Stark.
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Table 1: Sequences of primers used to PCR amplify genomic DNA for 311C, 072C and 382C. 
Primers 890 and 861 for 311C, 891 and 892 for 072C and 893 and 894 were used for 382C.
Primers Sequences
C. merolae’s 
genes
FWD
OSDR890
5' CCGAATTCCGTGTACGGCTTCGCACTTGCG 3'
311C
REV
OSDR861
5' CTCGCGACCCATCATCTTACGCAAC 3'
FWD 
OSDR 891
5' CCGGAATTCGGCAAGGACTACGCACGCCCGAAC 3'
072C
REV 
OSDR 892
5 'CCGGGATCCCATCCGATGCCACAGGGCGCGAGAC 3'
FWD 
OSDR 893
5 'CCGGAATTCCGGCCGAGTCGCGAGTAACCATTC 3’
382C
REV 
OSDR 894
5' CCGGGATCCGAGGTCAAAGAGTCGCACCGCGCC 3’
FWD 
OSDR 1000
5' CCG ATAG A ATTCGCGGTTCCCGTTATCGTCTGGTGGG3'
067C
REV 
OSDR 1001
5' CCGATAGGATCCGCACACGCTCGTCATAGTCCAGACC3'
FWD 
OSDR 1002
5' CCG AT AG A ATTCGCCG ATCGCC AAT ATT AGCCG ATG 3'
350C
REV 
OSDR 1003
5' CCGATAGGATCCCGTCTTTGGCAGAGTCATCGATCCC 3'
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2.2.4 Preparation of the glycerol gradient
Gradients were performed in the ultracentrifuge tubes as described in (Brody, et al. 1985) with 
modification of 15% and 40% (v/v) glycerol stock solutions. Solutions were prepared in standard 
gradient buffer (20 mM Hepes-KOH (pH 7.9), 150 mM NaCl (or KC1), and 1.5 mM MgCh). A 
30pl splicing reaction, containing 40% (v/v) whole cell extract in dialysis buffer (20 mM Hepes- 
KOH (pH 7.9), 50m M KC1, 0.5mM Dithiothrreittol, 0.2 mM EDTA (pH 8.0), 20% (v/v) 
glycerol), with 25 mM MgCh, 1M creatine phosphate, 10 mM ATP and 12 fmols of 32P labelled 
pre-mRNA in standard 1.5mL tube, was incubated for 5 minutes at room temperature and 
samples were run over l lmL glycerol gradients. Gradients were centrifuged for 12 hours at 
35,000rpm at 4°C in a (SW41TI 331/372) rotor. After spinning the ultracentrifuge tubes were 
taken out and the samples were fractionated from top to the bottom. Each fraction contained 
400pl of the glycerol gradient and 600pl of scintillation liquid was added to it to measure 
radioactivity.
2.2.5 Splicing Assays
Standard splicing assays were performed according to (Schwer & Guthrie, 1991). Each reaction 
was performed in lOpl reaction containing 2.5 mM MgCh, 60 mM KP04, 3% PEG, 40% yeast 
whole cell extract, 10 mM ATP and 4 fmol of internally 32P-GTP labeled precursor mRNA. The 
reactions were incubated for 30 min at 27°C and then kept on ice before loading on gel.
2.2.6 Spliceosome Assembly Gels
Spliceosomal complex assembly was analyzed as described (Kelly G et al. 2009). In order to 
separate individual spliceosomal complexes, aliquots of splicing reaction containing 32P- labeled
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transcript were taken at different times and run on non-denaturing 4% polyacrylamide gels (80:1 
acrylamide/bis-acrylamide) at 160 V for 3 h in TGM buffer (50mm tris base, 50mM glycine, 
2mM MgCh). The dried gels were then exposed to a Phospholmager screen for visualization 
overnight.
2.3 Results
We tried the same methodology as in (Brody et al. 1985) in order to study the spliceosome in 
Cm. For this purpose 382C Cm pre-mRNA was used. In each experiment, a splicing reaction 
without splicing extract and another without ATP was also run over gradients in order to have 
control for non-ATP-dependent particle assembly (i.e. due to processes other than splicing) and 
non-extract-dependent changes in RNA mobility (e.g. due to buffer).
Figure 6(a) shows the number of radioactive counts as a function of position in the glycerol 
gradient for 382C pre-mRNA in Cm splicing extract. The gradient without any splicing extract, 
containing only pre-mRNA (blue) in splicing buffer, shows a peak on top o f the gradient 
(fractions 5-9). When splicing extract and ATP were added to pre-mRNA (red), the peak shifted 
further into the gradient (fractions 8-13). The gradient without any ATP and only pre-mRNA and 
splicing extract has a peak even further down the gradient (green, fractions 16-20). This graph 
suggests that spliceosome assembly is occurring on the pre-mRNA as it is pulling the RNA into 
the gradient when ATP and splicing extract is added to it. We further performed glycerol 
gradient experiment with 382C mature mRNA (intronless) in order to confirm that peaks 
observed with pre-mRNA are due to assembly on introns. Figure 6(b) is another graphical 
representation of gradients with mature mRNA. No peak is observed in any of the gradient when 
intronless RNA is studied for spliceosome assembly. The pattern of graphs for 382C mRNA
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looks similar in all three gradients as compare to the gradients done with 382C pre-mRNA. This 
experiment showed a clear difference o f spliceosome assembly (showing assembly only with 
pre-mRNA) on 382C pre-mRNA and matures mRNA.
(a ) 382C pre-mRNA
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Figure 6: Comparison of spliceosome assembly in 32P labelled 382C pre-mRNA and 
mRNA. The amount of 32P in each fraction is measured and fractions with high radioactivity 
show the presence of pre-mRNA. (a) 382C pre-mRNA in Cm whole cell extract shows 
spliceosome assembly, (b) 382C mRNA in Cm extract shows no assembly at all. Graph looks 
similar for gradients all three gradients.
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Glycerol gradient sedimentation was further performed with three other Cm pre-mRNAs. Figure 
7 shows the gradients with 311C, 067C and 072C pre-mRNAs. As seen by the distribution of 
radioactivity in each gradient, (Figure 7(a)), the position of peaks in all three gradients for 311C 
is similar, and the entire radioactivity lies near the top of the gradient, indicating that nothing in 
the extract associates with this transcript. Similarly, experiments with 067C and 072C (7(b) and 
7(c)) showed that there was no difference in the position of the peaks with either of these 
transcripts. As above, one of the gradients was with ATP (blue) and other was without ATP 
(red). In order to measure the difference in peaks, gradient centrifugation was repeated three 
times with each of the Cm transcripts. These experiments showed a similar pattern o f labelling in 
all fractions of the gradients with and without splicing extract and also ±ATP. All the Cm 
transcripts selected for glycerol gradient sedimentation are listed in Table 2. It has been found 
that 22 genes in Cm have canonical 5' splice sites, while there are five genes that have different 
5' splice sites. The genes listed in Table 2 include different types of 5' splice sites.
Table 2: C. merolae transcripts (txt) with their different 5' splice sites. The transcripts with 
different 5' splice sites were checked by gradient centrifugation and assembly gels.
Cm. txt Pre-mRNA
(bp)
mRNA
(bp)
5' splice site
382C 718 411 GUAAGU
072C 501 416 GUAAGU
311C 474 359 GUAAGU
067C 475 400 GUAAGC
350C 466 362 GUAGGU
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(b)
14
(C)
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Figure 7: Glycerol gradient analysis of 311C, 067C and 072C. All pre-mRNAs were 
subjected to similar splicing conditions as for 382C pre-mRNA and radioactivity was measured 
in each fraction.
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As a positive control for this method, we have also done glycerol gradients with yeast extract 
using 32P labelled yeast actin pre-mRNA. Figure 8 shows the graph of these experiments. As 
indicated by the graph, there is a substantial increase in the sedimentation rate in the presence of 
splicing extract (with or without ATP). That the position of the peak did not change upon 
addition of ATP may simply be a reflection of the short incubation time (5 min) in these 
experiments.
3XMS2 Actin Pre-mRNA
16.00
14.00
12.00
m 10.00
8.00
® 6.00
Q. 4.00
2.00
0.00
1 3 5 7 9 13 1511 17 19 21 23 25 27 29
(No Ext) -*-(+ATP) — -(-ATP)
Figure 8: Graphical representation of glycerol gradient performed in yeast system with 
actin. 32P labelled yeast actin was incubated with yeast whole cell extract and centrifuged for 12 
hrs at 35,000 rpm. The radioactivity of each gradient fraction was measured.
2.3.1 Splicing gels
In order to study spicing in C. merolae, we used C. merolae pre-mRNA in splicing extract for all 
assembly gels as well as standard splicing assays. Actin pre-mRNA with yeast splicing extract 
was used as a control in all of our experiments. Previous studies have shown that the MS2
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hairpin can be attached to pre-mRNA and standard splicing assays can be done on it without any 
interference of MS2 with any of the splicing components. Three MS2-binding sites can be fused 
to the 5' end of actin and C. merolae pre-mRNAs. Both tagged and untagged pre-mRNAs can 
then be studied in splicing and assembly gels. Studies have also shown that truncation of the 
actin pre-mRNA in the splicing reaction can lead to stalling of the spliceosomal cycle (Cheng et 
al. 1994).
We have applied the same methodology to make MS2 tagged and truncated transcripts. To purify 
C. merolae splicing factors out of extract, we made a pre-mRNA construct tagged with MS2 
sequences that could be pulled down with the MS2-binding protein. In order to make MS2 
tagged constructs, the 3XMS2 actin construct was cloned into pUC19. Gel electrophoresis in 
Figure 9 confirmed the presence of 3XMS2 actin in pUC19 when it is double digested with 
EcoRI and HINDIII. Nine out of ten colonies showed the presence of inserts.
Once actin has been cloned into pUC19, truncated and untagged constructs were made from 
original plasmid with 3XMS2 actin. Truncated actin, lacking the 3' splice site, is made by 
removing 200 bp downstream of the branch site of the intron. Gel electrophoresis has confirmed 
the formation of truncated and untagged actin in pUC19 (Data not shown).
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Figure 9: Gel analysis showing the presence of 3XMS2 actin in pucl9: Nine different 
colonies are tested by doing double digestion with EcoRI and HinDIII. Lane 1 is 1 kb ladder.
Next C. merolae genes were cloned into pUC19 by removing actin from the plasmid and 
inserting Cm genes into it. PCR products from Cm were cut with EcoRI and BamHI and gel 
extracted. In order to insert each PCR product of C. merolae into the vector, three ligations were 
done with each PCR product. The presence of insert in each MS2 tagged construct was 
confirmed by digesting the plasmid with EcoRI and BamHI and then running it on the agarose 
gel. Figure 10 shows the presence of Cm genes (311C and 382C) in pUC19], All samples show 
the presence of insert in the construct. Once we made tagged (MS2 X3) constructs, all these 
plasmids were linearized and in vitro transcribed to make RNA for splicing assays.
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DNA
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actin
Figure 10: Confirmation of presence of C. merolae’s genes in MS2 tagged construct. Two
different samples are taken for each C. merolae gene. Gene 382C is 718bp long (lanes 5, 6, 7), 
and 311C is 475bp in length (lanes 2, 3, 4). Actin is 590bp long (lanes 8, 9, 10). Lane 1 is low 
molecular weight DNA ladder, with brighter bands at 200 bp and 766 bp (top band).
Untagged (without MS2) construct was also made for all PCR products of C. merolae. Gel 
analysis also confirmed that these construct have C. merolae genes and no MS2. Each construct 
was then digested with HinDIII to make linearized plasmid for in vitro transcription.
The abilities of pre-mRNAs to undergo spliceosome formation were checked by doing assembly 
gels. For this purpose, splicing assays were performed initially with both tagged and untagged 
pre-mRNAs to test whether the MS2 binding sites inhibit splicing. As shown in Figure 11, 
splicing assays were done with untagged, 3XMS2 tagged and 3XMS2 tagged truncated actin and 
run on the gel.
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Figure 11: Standard splicing assay. Splicing reactions with and without ATP was done with 
different kinds of actin. Each lane with ATP for untagged and tagged actin shows the presence of 
mRNA. Splicing reaction with ATP for truncated actin does not show any band for mRNA.
To confirm that our system worked as previously described, we used yeast actin pre-mRNA with 
yeast extract as a positive control. This experiment (Figure 11) was performed to test the activity 
of untagged and tagged actin as well as truncated actin. With each 32P labelled pre-mRNA, a 
splicing assay was done with and without ATP in yeast whole cell extract. All the lanes with 
ATP showed the formation of mRNA except for truncated actin, which should not be spliced as 
it lacks a 3' splice site. Once the conditions for splicing assays in yeast were worked out, splicing
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efficiencies of C. merolae pre-mRNAs in yeast as well as in Cm splicing extracts were checked. 
Initially, Cm pre-mRNAs were tested in yeast whole cell splicing extract as shown in Figure 12. 
Two of the 3XMS2 tagged Cm pre-mRNAs were tested in this splicing assay along with tagged 
actin pre-mRNA (control). This splicing gel shows that none of the Cm pre-mRNAs spliced in 
the yeast splicing extract, as all the lanes with ATP did not show any band for mRNA except for 
the control lane (actin), which spliced in yeast extract as seen before in the previous gel.
CZZHZZ3
actin 311C 382C
Yeast Extract
Figure 12: Splicing assays done with Cm pre-mRNAs. Actin is used in first two lanes. 
Addition of ATP resulted in formation of mRNA for only actin (first lane). All the lanes with 
ATP for 311C and 382C do not show any band for mRNA.
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2.3.2 Stalling the Cm spliceosome at different stages
To assess the progress of splicing over time, assembly gels were used on splicing reactions 
allowed to proceed for different lengths of time. For each time course, splicing mix with 32P 
labelled pre-mRNA and 2mM ATP was incubated at room temperature and then the reaction was 
stopped by placing it on ice until loaded onto the gel. Spliceosome assembly was detected by 
electrophoresis on non-denaturing (native) gels (Figures 13, 14 and 15). Assembly gels were 
initially done with 3XMS2 tagged and truncated actin in yeast splicing extract.
Figure 13 shows the pattern of different assembly stages in yeast at different time points. At the 
zero min time point, only pre-mRNA can be seen on the gel, while later on as the time proceeds 
from 5 to 30 min, the spliceosome passes through stages A (mostly at 5), and then B (Bact and C 
are not visible under the conditions of these gels). Under the same conditions, the truncated pre- 
mRNA behaved differently than full length pre-mRNA as an extra band was observed (top band 
in lanes with truncated actin), which I interpret to be complex C.
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Figure 13: Kinetics of splicing complex formation. First five lanes show assembly stages in 
actin; whereas last five lanes show assembly pattern with truncated actin.
Spliceosome assembly patterns with Cm pre-mRNAs were initially studied in yeast splicing
extract, as a control for the method, rather than Cm extract. Actin pre-mRNA was also used as a
control in the same experiment. As shown in Figure 14, 311C Cm pre-mRNA does not go
through any of the splicing stages (in a 0 to 30 min time course) as there is no band in any lane
other than the pre-mRNA. In contrast, all the lanes with 382C pre-mRNA have an additional
band above the pre-mRNA, which may be indicative of assembly.
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Figure 14: Spliceosome assembly with actin and Cm pre-mRNAs. Each lane represents a 
different time point, starting from 0 to 30, for each of the transcript. Top two bands, A and B, 
represent assembly stages in the spliceosome.
Similarly, other Cm pre-mRNAs (072C, 067C and 350C) were also used in assembly gels with 
yeast as well as Cm splicing extract, but none of them have shown any assembly in either of the 
splicing extracts (data not shown). Figure 15 is one of the gels where Cm splicing extract was 
used to check for assembly with 3XMS2 tagged actin. After checking assembly of the Cm pre- 
mRNAs in Cm splicing extract and not being able to see any assembly (data not shown), Cm
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splicing extract here was checked again for assembly with actin pre-mRNA to test whether it 
might splice more efficiently. As shown in Figure 15, spliceosome assembly can be seen only 
with yeast extract and not with Cm splicing extract.
Cm Extract Yeast Extract
2mM
3XMS2 Actin
ATP
<4f *  B
4 — A
Figure 15: Comparison of spliceosome assembly in yeast and Cm splicing extracts. Actin is 
used here to study assembly pattern in yeast as well as Cm extract. Each lane represents different 
time point during spliceosome assembly. First half of gel represents assembly in Cm extract 
whereas second half (right) represents assembly in yeast splicing extract.
34
2.4 Discussion
To study spliceosome assembly in Cm by glycerol gradient sedimentation, we have utilized the 
protocol developed for yeast. Our graph representing accumulation of complexes throughout the 
glycerol gradient for the Cm 382C pre-mRNA and mature mRNA has given us very promising 
indication that the spliceosome is assembling onto the pre-mRNA in Cm extracts. We can see by 
the patterns of peaks in Figure 6(a) that without any splicing extract, nothing is assembling onto 
the 382C pre-mRNA and therefore all the radioactivity is seen at the top of the gradient. The 
peak shifted further down the glycerol gradient when splicing extract and ATP were added in 
another gradient (red). This is likely due to the assembly of spliceosomes on the pre-mRNA in 
Cm. The shift in the position of the peak in the gradient without ATP might be because early 
steps of spliceosome assembly do not need any ATP. For example, in yeast the U1 snRNP can 
bind to a transcript in an ATP-independent manner. Spliceosome assembly on the Cm 382C 
transcript was further confirmed by doing another gradient with mature mRNA in a Cm splicing 
extract. As shown in Figure 6(b), no peak was seen in any of the gradients, indicating that the 
assembly seen previously with pre-mRNA was intron-dependent and without any intron the 
spliceosome did not assemble onto the RNA. Therefore, we further checked spliceosome 
assembly on three other Cm pre-mRNAs to confirm our hypothesis that the peaks seen with 
382C pre-mRNA were due to spliceosome assembly in Cm. As shown in Figure 7, no other Cm 
transcript behaves as was seen with 382C. Gradients with all the Cm pre-mRNAs showed 
different patterns of sedimentation than expected for spliceosome assembly. There is no 
observable difference in peaks for the gradients with and without ATP, indicating that 
spliceosomes did not assemble on these pre-mRNAs.
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In order to study spliceosome assembly biochemically for the first time in Cm, it is important to 
test the methodology on a known organism whose spliceosome has been studied biochemically 
and compare our experimental results with it and follow the same protocol initially that worked 
out for that particular organism. Here, we have selected yeast as an organism that could be used 
as a control for our experiments. The first step is to replicate previous splicing experiments in 
yeast using different forms of actin (tagged and truncated actin pre-mRNA). Splicing was 
performed with different forms of actin pre-mRNA and Figure 11 explains that both tagged and 
untagged actin pre-mRNA spliced at the same level, indicating that the MS2 binding site does 
not inhibit splicing. It also confirmed that truncated pre-mRNA was not fully spliced as it lacks 
3' splice sites, so it can be used for stalling the later assembly step of the spliceosome in an 
assembly gel. Although splicing was seen in yeast with actin pre-mRNA, when Cm pre-mRNAs 
were added to the yeast splicing extracts and subjected to splicing conditions, none of them 
spliced. In Figure 12 we can see that 311C and 382C did not show any band for mature mRNA, 
while actin was spliced to mRNA when ATP was added to it. Different Cm pre-mRNAs were 
subjected to splicing conditions in yeast splicing extract, but none of them spliced. We have also 
checked splicing of Cm pre-mRNAs in Cm splicing extracts, but none of them spliced either. 
Similarly we were unable to detect spliceosome assembly in Cm, but have observed assembly in 
yeast extract with actin pre-mRNA. According to yeast nomenclature, the spliceosome passes 
through E-A-B-Bact-C assembly stages, and we could clearly detect the A and B complexes.
Our gels showed the same assembly pattern expected for the yeast spliceosome according to the 
literature. Figure 13 shows that spliceosome assembly can be stalled at different stages in yeast 
(A, B and C). As MS2 tagged pre-mRNA was used to stall the assembly at different stages, it can 
further be used for affinity purification of spliceosome complexes. When assembly was studied
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in Cm, however, we were unable to get any of the spliceosome complexes. Figures 14 and 15 
describe that 311C and 382C are unable to go into any rounds of splicing when checked for 
assembly in yeast and Cm extracts respectively.
2.5 Conclusion
The overall study has provided us a medium for doing splicing reactions with MS2 tagged and 
untagged constructs. Glycerol gradient centrifugation was performed with four C. merolae 
transcripts in order to study spliceosome assembly. Gradients with 382C have shown that some 
assembly is going on as we can see a difference in peaks with and without extract. No clear 
difference was seen with and without ATP when other Cm transcripts were used. Our results 
suggested that different Cm pre-mRNAs behave differently. According to these experiments, 
under the same splicing conditions, some of Cm pre-mRNA undergoes spliceosome assembly 
and some does not. Our assembly gels showed that the conditions which we have optimized for 
the system worked well for yeast extract with actin pre-mRNA, and that fusion of MS2 binding 
sites to the pre-mRNA did not affect the splicing process and pre-mRNA passed through the 
normal splicing pattern in yeast. Also the truncated version of actin was able to go through early 
steps of spliceosome assembly. All the experimental conditions worked well for the yeast 
system, suggesting that our control conditions for the experiment worked well. When the same 
conditions were applied in the Cm system (i.e. with Cm splicing extract and pre-mRNAs), we 
were unable to see any splicing or assembly. The reason for this failure in Cm could be the 
splicing extract, being inactive, preventing assembling on the transcript. In the literature there is 
no known protocol for extract preparation in plants, and the extract used here was made 
according to the protocol used for making yeast whole cell extracts. So there is the possibility 
that pre-mRNA got degraded in the Cm splicing extract or the extract was not active at all. Some
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of the experimental conditions were also changed for the Cm System, keeping in mind that Cm 
may splice in conditions that are different from yeast splicing conditions. Those conditions 
included changes in ATP concentration from 2mM to lOmM in assembly gels, changing RNA 
concentration from 4 femtomoles to higher concentrations such as 10 fmols and 20 finols, and 
also changing the incubation temperature from 23°C to 27°C. These changes were not effective 
to bring about splicing in Cm.
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Chapter 3 
High-throughput assays for pre-mRNA splicing
3.1 Introduction
In Chapter 2, I showed evidence for spliceosome assembly in C. merolae by glycerol gradient 
centrifugation. To further study spliceosome assembly, it would be useful to block assembly by 
using small molecule inhibitors of splicing. This would help us to define particular steps of 
assembly and also help in identifying different spliceosome complexes. For this purpose, I first 
developed an assay in yeast where small molecules were tested for their inhibitory effects on 
splicing. The goal of this project was to develop a sensitive, high-throughput screen for inhibitors 
of pre-mRNA splicing that would allow the lab to test a library of small-molecule compounds 
provided by our collaborator, Dr. David Grierson (UBC.)
The term “small molecule” incorporates a large variety of different compounds including 
carbohydrates, proteins and nucleic acids, depending on what mechanism is being studied and 
what is required. Small molecules that bind to RNAs can be used in many aspects of biology, 
medicine and also to study roles of many of the splicing factors involved in pre-mRNA splicing 
(Wong et al. 2004; Zaman et al. 2003). It is known that many types of small molecules act as 
inhibitors of different kinds of biological RNA-catalyzed processes (Sucheck and Wong 2000), 
and, therefore, can be helpful in the investigation of RNA function. For example, small 
molecules inhibitors have been used to study the dynamic processes involved in splicing. Introns 
often contain termination codons with upstream protein coding sequences, and sometimes 
leakage of unspliced pre-mRNA into the cytoplasm can occur which results in the translation of 
aberrant proteins. Many genetic mutations cause improper skipping of exons which ultimately
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causes defects in expression of protein. Similarly, some mutations involve inclusion or exclusion 
of nucleotides which result in longer or shorter versions of exons along with altered splice sites 
which leads to variations in the splice location as well as loss of the reading frame. In order to 
understand more about these mutations, we need to understand more about the normal splicing 
patterns. Small molecule inhibitors could be useful tools for this investigation. Oligonucleotides 
can be used to inhibit the splicing process suggesting that oligonucleotides could eventually lead 
to effective therapies. These inhibitors have brought many advances in the field of splicing and 
have given us new ideas for drug development.
Many papers have been published about inhibitors of splicing, describing the mechanism in the 
inhibition of splicing, determining various components of the spliceosome, and developing 
effective drugs. The discovery of small molecules like antibiotics has made the study of 
ribosome much easier. Streptomycin and puromycin have provided information about translation 
mechanisms by blocking the ribosome at different levels, generating stalled complexes (Andreas 
et al. 2008). Similarly, spliceostatin A has been shown to inhibit in vitro splicing by binding to 
SF3b (subcomplex of U2 small nuclear RNA in spliceosome) (Daisuke et al. 2007). Different 
peptides have been used to block mammalian spliceosome assembly and pre-mRNA splicing. It 
has also been found that peptides, when designed corresponding to highly conserved sequences 
in interaction domains of proteins, inhibit in vitro splicing (Paul et al. 2003).
The objective of this study was to develop high-throughput screening methodology to assess the 
activity of small molecules in a yeast-based in vitro splicing assay. Our hypothesis was that 
small-molecule members of the indole family of compounds would act as inhibitors of the pre- 
mRNA splicing reaction in yeast splicing extracts. The specific aim was to use this yeast-based 
assay in Cm to find the inhibitors that stall the Cm spliceosome in order to better understand the
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assembly in Cm. These stalled complexes can then further be purified to study the components 
and composition by mass spectrometry.
The techniques used for this particular assay, gel electrophoresis and quantitative PCR, allowed 
us to determine the quantities of pre-mRNA and mature RNA present in splicing reactions. 
Traditional splicing assays rely on gel and radioactivity based assays. Since these assays are slow 
to perform, we developed a quantitative PCR method to test libraries o f small molecules. This 
method will allow us to achieve both the high-throughput screening of small molecules and 
quick determination of functional activity of these compounds.
3.2 Materials and methodology
For inhibition of splicing, the first step was to perform splicing reaction, and to check splicing 
efficiencies by gel electrophoresis or quantitative PCR (qPCR). For this purpose different sets of 
primers were made optimized. After identification of functional primers, the efficiency of crude 
splicing reaction (without phenol-chloroform extraction) was determined by qPCR. For this 
purpose different dilutions o f crude splicing reactions were made with water.
3.2.1 Splicing assays
Standard splicing reactions were performed in 10 pi reactions as described in Chapter 2. Some of 
the reactions were performed without adding ATP. Incubation was done at 23°C for 30 min. 
Splicing reactions were terminated by addition of 200 pi stop solution (3M NaoAc, 500mM 
EDTA, 10% SDS and E coli tRNA (lOmg/mL) ), extracted with phenol/ chloroform and ethanol 
precipitated. Crude splicing reactions (without phenol/ chloroform extraction) were diluted with 
water.
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Table 3: Sequences of primers designed for actin pre-mRNA as well as mRNA. Primer D is 
reverse and common to all forward primers. Primer A is unspliced specific, primer B is specific 
for both, spliced and unspliced. Primer C is spliced specific.
Primers Sequences Target area
FWD A 5' CAT GTA CTA AC A TCG ATT GCT TCA 
TTC3'
Intron- exon specific
FWDB 5' ATT AAC AAT GGA TTC TGA GGT TGC 
TGC3'
5' CAT GTA CTA AC A TCG ATT GCT TCA 
TTC3'
Specific to both, outer 
exons and junction exons
FWD C 5' ATT AAC AAT GGA TTC TGA GGT TGC 
TGC3'
Exon junction specific
REV D 5' GGC TGC AGG TCG ACT CTA GAG GAT C 3' Exon specific
3.2.2 Primer design
In order to check splicing efficiencies, primers were designed to amplify pre-mRNA and mature 
mRNA. The sequence and specific area of target for each primer is given in the Table 3 and 
block diagrams of all sets of primers is shown in Figure 16. Primer A is specific to pre-mRNA, 
primer B is specific to both pre-mRNA and mature RNA, and Primer C to mature mRNA.
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(a) Primer A
(b) Primer B 
*
(c) Primer C
Figure 16: Block diagram of primers designed for actin pre-mRNA and mRNA. Exons are 
represented by boxes and introns by line. Arrows represent the target area of primers on mRNA. 
(a) Primer A is unspliced specific, with the target area of pre-mRNA (intron-exon). (b) Primer B 
is specific to both pre-mRNA (unspliced) and mature mRNA (spliced), (c) Primer C is exon 
junction primer, specific to only mature RNA (spliced).
3.2.3 RT-PCR
Total RNA was treated with Turbo DNase (Ambion) and RT-PCR reactions were carried out 
using the appropriate primer pairs and Affinity Script reverse transcriptase (Stratagene) 
following the manufacturer’s instructions.
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3.2.4 Gel assay
PCR products were analysed on a 1.5% denaturing agarose gel. 6X loading dye (buffer) was 
added to each reaction and the reactions were then loaded onto the gel. Electrophoresis was 
performed at 120 volts, for 35 min and products were visualised by staining with ethidium 
bromide and exposing under UV light.
3.2.5 One step RT-qPCR
QPCR was used to measure splicing efficiencies using above primers. For this purpose, one step 
qRT-PCR was performed. Standard crude splicing reactions with 20fmol of actin were diluted 
with water to get different concentrations of actin. The diluted (1:100) splicing reactions were 
added to the QPCR reactions (50X RT mix (reverse transcriptase, RNase inhibitor and buffer), 
2X master mix (fluorescein reference dye at concentration of 10 nM) and primers at 
concentration of 2 mM. The reaction volume was selected as 20 pi and all the reactions were 
transferred to a QPCR plate for analysis.
3.3 Results
We wished to develop a rapid assay for pre-mRNA splicing in an in vitro extract, so we turned to 
PCR to measure the relative amounts of pre-mRNA and product mRNA under varying 
conditions. As mentioned earlier, the strategy applied initially in our assay development was to 
perform gel electrophoresis for all of the splicing assays in order to identify functional primers, 
and then QPCR was developed, as it is a quick method of determining splicing efficiencies when 
small molecules are being tested on a large scale. Initially we measured the efficiencies of
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phenol-chloroform extracted splicing reactions and then efficiencies of crude splicing reactions 
were determined using all sets of primers.
3.3.1 Gel Assays
In our first experiment, an attempt was made to check the efficiency of phenol-chloroform 
extracted splicing reactions, with primers B on 1.5% agarose gel. Primer B is specific to both, 
spliced and unspliced. Block diagram of the primer is shown in Figurel6. We initially checked 
20 fmol and 4 fmol splicing reactions, with and without ATP (±ATP). As shown in Figure 17, a 
reasonable amount of mature mRNA and pre-mRNA was seen with and without ATP, indicating 
the primers are amplifying both pre-mRNA and mature RNA at the conditions applied here. 
Primer A (specific to pre-mRNA only) was also checked for its activity in the same splicing 
assay, but we observed that this primer was not working at this stage. In theory, this primer 
should give stronger bands for -ATP than +ATP, but our results showed similar bands for both.
The primer A worked well when the experiment was repeated by changing the annealing 
temperature and selecting different temperatures of 65°C, 66°C, 68°C, 70°C and 72°C. As shown 
in Figure 18, the bands are observed at 65°C, 66°C and 68°C, suggesting that the optimal 
annealing temperature for primer A is above 60°C. Primer B amplified targets at 60°C, 
producing appropriate sized bands in reactions with and without ATP (Fig. 17). The band for 
unspliced pre-mRNA (-ATP) is more intense than the spliced mRNA band, because the size of 
unspliced RNA, having an intron, is bigger than the spliced (+ATP) mRNA, having only linked 
exons, and therefore binds more dye (Figure 17).
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DNA
ladder
4fmol 20fmol
+ATP -ATP -ATP +ATP
Figure 17: Measurement of efficiencies of phenol/chloroform extracted splicing reactions 
with primer B. For all splicing gels, cartoons to the right of the gel represent the pre-mRNA 
substrate; exons are represented by boxes and introns by a line. Lane 1, low molecular weight 
DNA ladder, Lane 2, +ATP, bands are seen for both pre-mRNA and mature RNA, Lane 3, -ATP, 
bands are seen for pre-mRNA, Lane 4, -ATP and lane 5, +ATP (4fmol), bands are seen for both 
pre-mRNA and mature mRNA.
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DNA 
ladder
4fmol
-ATP
65C 66C 68C 70C < — Temp
3 4
Figure 18: Optimization of annealing temperature for primer A by utilizing a temperature 
gradient. All reactions are -ATP with 20fmol actin. Lane 1, low molecular weight DNA ladder, 
lane 2, annealing temperature of 65°C, lane 3, 66°C, lane 4, 68°C, lane 5, 70°C, lane 6, 72°C. No 
products were observed at 70°C and 72°C.
Spliced specific primer (C) has also shown unexpected results at 60°C. So, we performed an 
experiment for primer C by selecting different gradients of 65°C, 66°C, 68°C, 70°C and 72°C. As 
shown in Figure 19, the primer gave nice bands for +ATP and no bands were seen for -ATP, as 
expected, suggesting that primer C works well at annealing temperature above 65°C.
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4fmol
< — Temp
Figure 19: Splicing efficiency for identification of appropriate annealing temperature for 
primer C (spliced specific). Lane 1, low molecular weight DNA ladder, lane 2 to lane 6, -ATP 
with different gradients of annealing (lane 2, 65°C, lane 3, 66°C, lane 4, 68°C, lane 5, 70°C, and 
lane 6, 72°C). No bands are seen for all -ATP reactions. Lane 7 to lane 11, +ATP with same 
gradients of annealing. Bands are seen at all temperatures. All splicing reactions are with 20fmol 
actin.
We further tested these functional primers in crude splicing reactions (without phenol- 
chloroform extraction). The efficiencies of 20 fmol crude and phenol/chloroform extracted 
splicing reactions were examined together in an experiment. All splicing reactions were without
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ATP (-ATP). Primer B was used and annealing temperature was selected as 60°C. Nice bands 
can be seen for both, crude and phenol/chloroform extracted (Figure 20) splicing reactions.
o 20fmol
g-so I 0C (/) 
CL -ATP
Figure 20: Measurement of efficiencies of both crude and phenol-chloroform extracted 
splicing reactions with primer B. Lane 1, low molecular weight DNA ladder, lane 2, plasmid 
as a control, lane 3, -ATP, phenol-chloroform extracted splicing reaction with 20fmol actin, lane 
4, -ATP, crude splicing reaction with 20fimol actin.
In order to confirm our analysis, we tested the crude splicing reactions again with primer B. 
Primer B is our control primer to check that we can get products for both spliced and unspliced 
products in the same reaction. This time, different dilutions of crude splicing reactions were 
made with water. Our results showed that we can dilute the 20 fmol crude splicing reactions to
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1:250 and even up to 1:500 because we were able to get bands at both dilutions (1:250 and 
1:500). As shown in Figure 21, nice bands can be seen for crude and phenol/chloroform 
extracted splicing reactions.
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Figure 21: Confirmation of efficiencies of crude splicing reaction using primer B again by 
making different sets of dilutions. All reactions are -ATP and 20 fmol. Lane 1, low molecular 
weight DNA ladder, lane 2, plasmid (actin in pBluescript) as a control, lane 3, 1:250 diluted 
splicing reaction, lane 4, 1:500 diluted splicing reaction. Splicing reactions for these two lanes 
were phenol-chloroform extracted. Lane 5, 1:250 diluted crude splicing reactions, lane 6, 1:500 
diluted crude splicing reactions.
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All crude splicing assays showed that we can perform our experiments without 
phenol/chloroform extraction, by diluting the splicing reactions up to 1:500 with water. We next 
confirmed the efficiencies of crude splicing reactions by QPCR.
3.3.2 QPCR analysis
QPCR analysis also confirmed the efficiencies of crude splicing reactions and primers. Results 
showed that 20 fmol crude splicing reactions can be diluted up to 1:1000. One step RT-QPCR 
was performed with primer A or primer C. As primer B gives two different products (spliced and 
unspliced) in the same reaction, which does not distinguish between multiple products, was not 
used for QPCR analysis.
For the initial QPCR experiment, annealing temperature was selected as 60°C. It was found that 
the difference in Ct (threshold cycle) values for +ATP vs -ATP, using both sets of primers, was 
not very large. Primer A is specific for an unspliced transcript, so the Ct value for -ATP should 
be low, while for +ATP it should be large and thus we expect there to be a significant difference 
between Ct values with and without ATP. Using primer A, an average Ct value of 27.4 for +ATP 
and 25.3 for-A TP was found (Table 4). Similarly using primer C (spliced specific), the Ct value 
for +ATP should be lower than -ATP. As shown in Table 4, an average Ct value of 23.1 was 
found for +ATP and 25.9 for -ATP. The difference in Ct values for (±ATP) was not very 
prominent.
A significant difference in Ct values for (+ATP vs -ATP) was observed when the experiment 
was performed at 65°C. As shown in Table 4, using primer C, the mean Ct value observed for 
+ATP was 22.0 and for -ATP, it was 30.6 at 65°C. Similarly when primer A was used in the 
experiment, the mean Ct values were 32.8 for +ATP and 27.4 for -ATP.
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Table 4: Ct (threshold cycle) values for ±ATP at 60°C and 65°C (annealing temperature).
QPCR was performed at both the temperatures (60°C and 65°C) and Ct (measure of 
concentration of target in the reaction) values were measured for each set of primers at the end. 
The reactions were done with and without ATP using primer A and C. Ct value is given in the 
table for each primer. This value can be lower or higher for ±ATP depending upon the set of 
primers used in the reaction. Ct value is higher for -ATP and lower for +ATP when primer C is 
used whereas this value is lower for -ATP and higher for +ATP when primer A is used.
ATP + -
Temp 60 °C 65 °C 60 °C 65 °C 60 °C 65 °C 60 °C 65 °C
Primer C C A A C C A A
Ct 21.8 18.9 22.9 32.8 23.9 30.2 20.7 26.9
Ct 20.1 20.9 22.6 31.7 23.8 28.2 20.9 26.5
Ct 27.1 18.0 31.1 30.3 33.6 27.5 30.0 25.9
Ct 26.3 18.8 25.3 35.3 29.3 34.7 23.7 26.7
Ct 21.4 28.9 31.0 35.4 22.5 31.3 30.2 29.3
Ct 21.7 26.3 31.7 31.1 22.2 31.9 26.5 28.8
CtMean 23.1 22.0 27.4 32 J 25.9 30.6 25.3 27.4
Table 5 shows the difference in mean Ct values at both the temperatures (60°C and 65°C). A 
significant amount of difference can be observed by looking at the mean Ct values given at the 
end of table.
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Table 5: Ct (threshold cycle) difference for ±ATP at 65°C and 60°C (annealing 
temperature). First two rows represent difference in Ct values for ±ATP with primer A and last 
two rows represent the difference in Ct with primer C. Mean Ct is given at the end of each row. 
At 65°C, the difference in mean Ct value for both ±ATP is more prominent as compare to Ct 
values at 60°C.
Ct Difference (±ATP) 
at 65 °C
Ct Difference (±ATP) 
at 60 °C
Ct Difference (±ATP) 
at 65 °C
Ct Difference (±ATP) 
at 60 °C
Primer A Primer C
5.9 2.2 11.3 2.1
5.2 1.7 7.3 3.7
4.4 1.1 9.5 6.5
8.6 1.6 15.9 3.0
6.1 0.8 2.4 1.2
2.3 5.2 5.5 0.5
5.4 2.1 8.7 2.8
Difference in Ct values of (±ATP) splicing reactions at both the temperatures was measured with 
primer A and C. It has been found that difference in +ATP vs -ATP at 65°C is more prominent 
and detectable as compare to 60°C. The significance of this difference was confirmed by 
applying student’s t Test. Figure 22 confirms the significance of difference in (±ATP) at 65°C 
while at 60°C, this difference is not significant.
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Figure 22: Difference in Ct values for +ATP vs -A TP a t 60°C and 65°C. Primer A is pre- 
mKNA specific, while primer C is mRNA specific. The difference in +ATP vs -ATP at 65°C is 
calculated by Student's /-Test to be significant (P value is 0.002 for primer C, while for primer A 
P value is 0.0004). At 60°C, the difference in +ATP vs -ATP is not significant, as the P value 
using Student's /-Test for Primer C is 0.23 whereas for Primer A, the P value is 0.42.
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3.4 Discussion
Our results demonstrated that the primers designed for this particular project were able to 
amplify the actin pre-mRNA and mature mRNA. Initially, optimal annealing temperature of each 
of primer was tested. As shown in Figure 17, when primer B was used in an experiment with 
annealing temperature of 60°C, this primer worked well, suggesting that the quantities of both 
pre-mRNA and mature RNA can be determined using primer B at this annealing temperature. 
Primer A however was unable to amplify pre-mRNA at 60°C but when it was tested again by 
selecting different temperatures, it worked well. This primer should amplify only pre-mRNA, by 
giving stronger band for it than for mRNA and it was obvious this time where other temperatures 
were used (Figure 18). This experiment has confirmed the appropriate annealing temperature for 
primer A. Similarly primer C was tested (Figure 19) at different temperatures in order to select 
an appropriate annealing temperature for it. The Figure shows that this primer is works well at 
65°C, 66°C and 68°C.
These experiments have given us appropriate annealing temperatures for our primers in splicing 
reactions that were extracted with phenol-chloroform to remove proteins from RNA. Once we 
were able to get functional primers with phenol/chloroform extracted splicing reactions, the next 
step was to check the functional primers with crude splicing reactions (without phenol- 
chloroform extraction). Since we had 300 small molecules to test as potential inhibitors, we 
needed to analyze a large number of splicing reactions, so it was important to minimize the 
amount of sample handling. For this purpose we checked out functional activities of all these 
primers in crude splicing reactions and have done gel electrophoresis after PCR. Figure 18 and 
19 showed that the primers were also functionally active in splicing reactions where RNA was 
not separated from proteins. As both the phenol-chloroform extracted and crude splicing
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reactions were used in the same experiment and were treated with primer B, the intensity of 
bands was similar in both cases. So it was obvious from these experiments that crude splicing 
conditions could be used to determine the inhibitory activity of small molecules.
Figure 20 and 21 explain the functional activity of primers in crude splicing reactions at their 
specific annealing temperatures by using different dilution of splicing mix. All crude splicing 
reactions also worked well with different dilutions.
QPCR analysis has also confirmed that both the primers (A and C) are amplifying actin pre- 
mRNA and mRNA respectively at annealing temperatures of 65 °C. Table 4 and 5 explains the 
Ct values for both the primers at different temperatures. It can be observed that significant 
amount of difference in Ct values can be seen at 65°C as compare to 60°C. This data suggested 
that the appropriate annealing temperature for these primers is 65°C (Figure 22). As at this 
temperature the difference in +ATP vs -ATP is more detectable and is also confirmed by 
student’s t Test.
I have developed the assay mentioned above and have found that the difference in +ATP vs - 
ATP can be detected using positive control in both QPCR and gel assays in the absence of small 
molecules. To explore that how the small molecules can inhibit splicing, further investigation 
was carried out by another lab member (Dr. Jeff Northrop). He has performed the entire screen 
with 250 small molecules (indole derivatives) and found that the assay is working well as the 
known inhibitors were distinguishable from no inhibitors. However, none of the small molecules 
was able to inhibit the splicing assay as no difference was observed in the Ct values with and 
without small molecules.
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3.5 Conclusion
The overall study has provided the tools for addition of small molecule inhibitors to standard 
splicing reactions in yeast. To identify novel splicing inhibitors, we wished to screen large 
libraries of compounds, which required development of a high throughput splicing assay. We 
chose to use quantitative RT-PCR as a rapid method to measure splicing efficiency with actin 
reporter construct. Primer sets were designed and tested to allow accurate differentiation between 
spliced and precursor mRNA, and liquid handling procedures were worked out to facilitate 
QPCR without inhibition by carry-over of the splicing reagents. To date, we have screened 250 
indole-derived compounds, none of which inhibited splicing. As we were unable to find 
inhibitors of splicing in yeast, we did not carry out further investigation in Cm to study its 
spliceosome.
Based on the investigation carried out in this research, it can further be used in future in order to 
investigate the inhibitors of splicing in Cm and then its spliceosome can be studied by purifying 
the stalled spliceosomal complexs and their analysis for protein composition as well snRNAs.
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CHAPTER 4
Conclusion
Our interest in characterizing the spliceosome of Cm comes from a desire to study the splicing 
reaction in a reduced and simpler system. This will allow us to study the role of individual 
factors in splicing. As discussed in the introductory chapter of this thesis, splicing has been 
studied previously in various organisms, primarily yeast and humans. These studies have 
identified different patterns of spliceosome assembly as well as different spliceosome 
composition at different steps. Due to the complexity of the human and yeast spliceosomes, C. 
merolae provided a more tractable system to study splicing. The goal of this work was therefore 
to investigate and characterize spliceosome assembly in C. merolae. As bioinformatic analysis 
has confirmed the dramatically smaller set of splicing machinery, we wished to characterize the 
spliceosome of Cm using biochemical methods. This was the first biochemical investigation of 
the Cm spliceosome. This research work has therefore highlighted a new direction to study the 
mechanism of splicing.
Initially, an attempt was made to measure the size of Cm spliceosome by glycerol gradient 
centrifugation. Glycerol gradient centrifugation was expected to reveal a similarly-sized particle 
independent of the pre-mRNA transcript used, as the size should depend primarily on the much 
larger spliceosome. These experiments did not provide information about the size of spliceosome 
with any of the Cm transcripts except for 382C. Gradient centrifugation of 382C mature mRNA 
showed a size reduction as compared to the 382C pre-mRNA under the same experimental 
conditions. This reduction in size is suggestive of spliceosome assembly on pre-mRNA. All the 
other pre-mRNAs did not show any assembly. This difference in the behaviour of Cm transcripts
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was seen in gradient centrifugation repeatedly, showing that different Cm pre-mRNAs behave 
differently under same experimental conditions.
Once the size of Cm spliceosome was measured by gradient centrifugation, assembly gels were 
performed to characterize spliceosome assembly in Cm. As a control, the investigation was 
carried out initially in yeast, knowing that the yeast spliceosome can be studied by assembly 
gels. Cm spliceosome assembly was then explored using the same protocol as used in yeast. 
Assembly gels provided the same pattern of spliceosome assembly in yeast as seen in the 
literature whereas in Cm, these gels were unable to define distinct spliceosomal stages of 
splicing.
The reason that assembly gels and gradient centrifugation experiments did not work in Cm may 
have been due to inactive Cm  splicing extract. As the Cm  extract used in this research was made 
according to the protocol used for making yeast splicing extracts, it may not have contained the 
necessary splicing components from Cm. The Cm  transcripts were rapidly degraded in the 
splicing extract. No active plant splicing extracts have been reported in the literature, perhaps 
because of the abundance of proteases and nucleases in plants.
Similarly, an attempt was made to identify small-molecule inhibitors of splicing that could be 
used to trap the Cm splicing reactions at intermediate steps. Since we do not yet have a 
functional in vitro splicing assay with Cm, this work was conducted with yeast extract. Previous 
work has demonstrated that some inhibitors are active in more than one species. Unfortunately, 
none of the compounds tested had any inhibitory activity. Once a Cm splicing extract is 
available, existing splicing inhibitors can be tested for activity against Cm splicing, and screens 
can be performed for Cm-specific inhibitors.
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The gradient centrifugation and assembly gels in Cm can be repeated in the future by making an 
active Cm splicing extract. Successful development of an in vitro system for studying Cm 
splicing would open the door to a wide array of experiments for characterizing the spliceosome 
and its distinct stages in Cm. Such experiments will play a key role in identifying the different 
intermediate stages in Cm splicing. This will enhance the overall understanding of the 
mechanism by which pre-mRNA splicing is accomplished in Cm.
Through the research work in thesis, I have polished and enhanced my understanding about the 
techniques and experimental analysis of pre-mRNA splicing. This has given me a confidence to 
peruse my research at a higher level. The knowledge and information that I have gained through 
this research, has incredibly increased my scientific skills and has made me more enthusiastic 
and motivated to gain advance knowledge in the field of splicing.
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